CME in Minutes: Education in Oncology & Hematology
Answers in CME
158 episodes
1 week ago
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
All content for CME in Minutes: Education in Oncology & Hematology is the property of Answers in CME and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs
CME in Minutes: Education in Oncology & Hematology
1 hour 17 minutes 43 seconds
3 weeks ago
Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs
Please visit answersincme.com/860/98336099-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss use of antibody-drug conjugates (ADCs) for patients with hormone-receptor (HR)–positive, HER2-low and -ultralow metastatic breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of HER2-low and ultralow status in patients with metastatic breast cancer (mBC); Integrate testing strategies for HER2-low and ultralow mBC; Evaluate the clinical data for antibody drug conjugates (ADCs) in HER2-low and ultralow mBC; and Propose practical strategies to enhance the current and future use of ADCs in HER2-low and -ultralow mBC.
CME in Minutes: Education in Oncology & Hematology
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
